NCT07804004

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease

RecruitingPHASE1, PHASE2INTERVENTIONAL

Trial Details

Start: 2026-09-15Est. Completion: 2029-12-30

Enrollment target: 220 participants

B-cell Mediated Autoimmune Disorders

The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-c…

La Jolla, United StatesEst. completion Dec 1, 2026

Progressive Multiple Sclerosis

This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kine…

Darlinghurst, AustraliaEst. completion Jun 14, 2030

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.